Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inhibikase Therapeutics (IKT) Revenue (2020 - 2023)

Inhibikase Therapeutics (IKT) has disclosed Revenue for 4 consecutive years, with $1.0 as the latest value for Q4 2023.

  • Quarterly Revenue fell 100.0% to $1.0 in Q4 2023 from the year-ago period, while the trailing twelve-month figure was $1.0 through Sep 2024, down 100.0% year-over-year, with the annual reading at $260501.0 for FY2023, 111.03% up from the prior year.
  • Revenue for Q4 2023 was $1.0 at Inhibikase Therapeutics, down from $79569.0 in the prior quarter.
  • The five-year high for Revenue was $1.4 million in Q1 2021, with the low at $1.0 in Q4 2023.
  • Average Revenue over 4 years is $261438.4, with a median of $72045.0 recorded in 2023.
  • The sharpest move saw Revenue skyrocketed 3169.86% in 2022, then crashed 100.0% in 2023.
  • Over 4 years, Revenue stood at $170416.0 in 2020, then plummeted by 98.86% to $1944.0 in 2021, then surged by 3169.86% to $63566.0 in 2022, then plummeted by 100.0% to $1.0 in 2023.
  • According to Business Quant data, Revenue over the past three periods came in at $1.0, $79569.0, and $116410.0 for Q4 2023, Q3 2023, and Q2 2023 respectively.